ReviewCancer cell international2026
Kaempferol-based nanocarriers as a potential therapeutic strategy against drug-resistant lung cancer.
Review in Cancer cell international, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Lung cancer is the predominant cause of cancer-related deaths, with chemoresistance posing a significant challenge for effective treatment. Drug resistance in lung cancer cells involves various cellular and molecular mechanisms, including the upregulation of DNA repair pathways, activation of secondary proto-oncogenes and alterations in cell cycle regulation, apoptosis and the tumor microenvironment. Recent advances in nanotechnology have paved the way for innovative approaches to overcome chemoresistance, particularly through the utilization of nanocarriers for targeted drug delivery. When encapsulated within nanocarriers, kaempferol's therapeutic potential is significantly enhanced, offering improved bioavailability, targeted delivery and reduced systemic toxicity. Kaempferol-based nanoparticles, including liposomes, solid lipid nanoparticles, and nanostructured lipid carriers, have shown substantial efficacy for combating chemoresistance in lung cancer models. These nanoparticles May enhance the intracellular delivery of kaempferol, potentially leading to the inhibition of key signaling pathways implicated in chemoresistance. Additionally, kaempferol-based nanocarriers have been shown to sensitize cancer cells to conventional chemotherapeutic agents, reducing drug efflux and enhancing apoptosis. The synergistic effects of kaempferol in combination with chemotherapy drugs, including cisplatin and 5-fluorouracil, further underscore its potential in overcoming resistance mechanisms. Moreover, the use of hyaluronic acid-modified, kaempferol-based nanoparticles has demonstrated enhanced targeting of lung cancer cells, inhibition of epithelial-to-mesenchymal transition and suppression of tumor invasion and metastasis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.